伊马替尼耐药慢性髓性白血病中miR-181c的下调
Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia.
作者信息
Mosakhani Neda, Mustjoki Satu, Knuutila Sakari
机构信息
Department of Pathology, Haartman Institute, and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
出版信息
Mol Cytogenet. 2013 Jul 16;6(1):27. doi: 10.1186/1755-8166-6-27.
The association of microRNA alterations with progression and treatment outcome has been revealed in different types of cancers. To find miRNAs involved in imatinib response we performed miRNA microarray followed by RT-qPCR verification of 9 available diagnostic bone marrow core biopsies from 9 CML patients including 4 imatinib-resistant and 5 imatinib-responder patients. Only one differentially expressed miRNA, miR-181c, was found when the imatinib-resistant group was compared with imatinib-responders. Significant down-regulation of miR-181c in imatinib-resistant versus imatinib-responders was confirmed by qRT-PCR. Some miR-181c target genes such as PBX3, HSP90B1, NMT2 and RAD21 have been associated with drug response.
微小RNA改变与癌症进展及治疗结果之间的关联已在不同类型的癌症中得到揭示。为了找到参与伊马替尼反应的微小RNA，我们进行了微小RNA微阵列分析，随后对9例慢性粒细胞白血病患者的9份可用诊断性骨髓核心活检样本进行了逆转录定量聚合酶链反应验证，其中包括4例伊马替尼耐药患者和5例伊马替尼敏感患者。当将伊马替尼耐药组与伊马替尼敏感组进行比较时，仅发现一种差异表达的微小RNA，即miR-181c。通过定量逆转录聚合酶链反应证实，与伊马替尼敏感患者相比，伊马替尼耐药患者中miR-181c显著下调。一些miR-181c靶基因，如PBX3、HSP90B1、NMT2和RAD21，已被证明与药物反应有关。
Zotero 插件